Home | Welcome to Contract Pharma   
Last Updated Tuesday, November 25 2014
Print

Galapagos Earns Janssen Milestone



Published January 16, 2013
Related Searches: Preclinical
Galapagos NV has identified a second preclinical compound in its alliance with Janssen Pharmaceutica NV, triggering a $5.3 million milestone payment to Galapagos.
 
The two companies entered the alliance in 2007, under which Janssen has option rights to acquire worldwide, commercial licenses to certain Galapagos internal programs.  
 
"We are very pleased to announce the delivery of a second candidate drug in the alliance with Janssen," said Onno van de Stolpe, chief executive officer of Galapagos. "Galapagos is progressing multiple programs successfully across different alliances and delivering promising candidate drugs."


blog comments powered by Disqus
Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:
Follow Contract Pharma On